Fidson Selected to Expand Influenza Treatment Access, Pandemic Preparedness

Fidson Healthcare Plc has been selected as one of eleven manufacturers across nine countries to sign sublicence agreements with the Medicines Patent Pool (MPP) for the development and manufacture of generic versions of baloxavir marboxil, an influenza antiviral. The agreement is under MPP's voluntary licensing agreement with Roche. This selection aims to expand access to influenza treatment and enhance pandemic preparedness.

Read More